# Is Ipamorelin FDA-Approved? Ipamorelin Regulatory Status > Is ipamorelin FDA approved? No — it failed its only Phase 2 trial, was never marketed, and in 2024 the FDA tightened 503A compounding access. The cited record. The short answer is no, and the long answer — a failed trial, a withdrawn nomination, a banned-in-sport listing — is more interesting than the short one. ## The short version The question is ipamorelin fda approved has a one-word answer: no. Ipamorelin has never been approved as a drug by the FDA — or by any other regulatory authority, anywhere — for any indication. That is not because it is new and still under review. It is because its clinical program effectively ended when its only Phase 2 trial, testing it for sluggish bowels after surgery, missed its goal [3]. Three facts fill out the picture. It was investigated and dropped, not merely never studied [3]. In 2024, the FDA tightened compounding-pharmacy access to it [11]. And it is banned in sport at all times, with the labs able to detect it in urine [7]. "Meds" in this site's name names a regulatory question this page answers honestly — it does not describe an approved medicine or a pharmacy. ## Never approved — and why that's a verdict, not a gap It is worth being precise about what "not FDA-approved" means here. For many research peptides, lack of approval simply reflects that no one ran the trials. Ipamorelin is different: the trials were run, at least to Phase 2, and the key one failed [3]. The only published Phase 2 randomized controlled trial (NCT00672074) gave 114 bowel-resection patients 0.03 mg/kg intravenously twice daily for up to 7 days and missed its primary endpoint — time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, not statistically significant (p=0.15) [3]. No Phase 3 trial followed, and no approved indication exists [3]. The originator, Novo Nordisk, had characterized the compound in the 1990s [1] and mapped its human pharmacokinetics in 1999 [2], but the efficacy program did not deliver. The absence of approval is the outcome of a failed development effort, not an unfinished one. ## The 2024 compounding decision Regulatory attention to ipamorelin did not end with the failed trial. In 2024, the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list — the framework governing which substances compounding pharmacies may use — following withdrawal of the nomination in September 2024 [11]. The agency reviewed both ipamorelin acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting [11]. The practical effect was to restrict compounding-pharmacy access to ipamorelin. It is not an approved bulk substance for compounding, and it remains marketed only as a research chemical. This is the most recent regulatory development and the one most relevant to how the compound circulates. ## Banned in sport, detectable in urine Separately from the FDA question, ipamorelin carries a clear anti-doping status: it is prohibited in sport at all times under the World Anti-Doping Agency Prohibited List, category S2 (peptide hormones, growth factors, and mimetics), as a growth hormone secretagogue. The prohibition is enforceable because detection is validated — accredited laboratories identify ipamorelin in urine at 2-10 pg/mL using high-resolution mass spectrometry [7], among several methods covering it and its metabolites [9][10]. So while it is not an approved medicine, it is very much a regulated substance — just under sport's rules rather than the drug-approval system. ## What the recent reviews conclude Independent reviews published in 2026 align with the regulatory record. A structured narrative review of injectable peptides in sports medicine classified ipamorelin as investigational, with no reproducible human evidence, recommending its use be confined to rigorous research protocols [16]. A review of approved and unapproved peptide therapies for musculoskeletal injury described it as investigational with preclinical signals but an absence of rigorous human trials and potential for serious harm [17]. The consistent message: ipamorelin is an unapproved, investigational compound — and the literature treats it as one. --- A naturalist's watch over the ipamorelin record — the molecule the anti-doping labs learned to catch at picogram traces, its single failed human trial kept openly in view, and community reports fenced off as unverified; no clinic, pharmacy, or product stands behind this page, and nothing here is dosed, prescribed, or sold.